Adagene Inc. Stock Price, News & Analysis

Adagene (NASDAQ: ADAG) reported updated data from its Phase 1b/2 study of ADG126 (muzastotug) in combination with KEYTRUDA for colorectal cancer treatment. The study showed promising results with 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer at the 20 mg/kg dose. Key highlights include: less than 20% Grade 3 adverse events, all six responders in 20 mg/kg cohorts remaining on treatment, and four patients continuing beyond 40 weeks. The 10 mg/kg cohorts demonstrated a median overall survival of 19.4 months with 17% ORR. The 20 mg/kg Q6W dosing showed equivalent efficacy with reduced toxicity compared to other regimens. The company plans to discuss the dosing regimen with regulatory bodies for the next phase of clinical development.

Adagene Inc. (Nasdaq: ADAG) has appointed Dr. John Maraganore as Executive Advisor to mentor the C-suite and provide strategic guidance. Dr. Maraganore, former CEO of Alnylam (2002-2021), brings extensive experience in developing breakthrough therapeutics and creating substantial market value.

The appointment aligns with Adagene's focus on their proprietary masking technology for checkpoint inhibitors, specifically ADG126, which aims to deliver anti-CTLA-4 therapy selectively to tumor cells while minimizing toxicity. During his tenure at Alnylam, Dr. Maraganore led the company through global approvals of four RNA interference medicines and formed over 20 major pharmaceutical alliances, building over $25 billion in market capitalization.

Adagene (Nasdaq: ADAG) has announced an upcoming poster presentation at the ASCO 2025 Annual Meeting in Chicago. The presentation will focus on their masked anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) therapy. The poster will showcase updated results from a Phase 1b/2 study examining the safety and efficacy of ADG126 in combination with Pembrolizumab for advanced MSS CRC treatment.

The presentation is scheduled for Saturday, May 31, 2025, with poster viewing from 9:00 AM to 12:00 PM CDT at McCormick Place, Chicago (Board #248, Abstract #3579). The poster will be accessible on the company's website Publications page.

Adagene Inc. (Nasdaq: ADAG), a pioneer in antibody-based therapy development, has announced its participation in Stifel's 2025 Virtual Targeted Oncology Forum.

The company's Chairman, CEO and President of R&D, Peter Luo, Ph.D., will deliver a corporate update and engage in one-on-one investor meetings during the virtual event scheduled for April 8-9, 2025. The presentation is set for Tuesday, April 8, from 12:30-12:55 PM Eastern Time.

Investors and interested parties can access the presentation webcast through the Investors section of Adagene's website (www.adagene.com), where it will remain available for a minimum of 30 days.

Adagene (NASDAQ: ADAG) reported its full year 2024 financial results, highlighting significant progress in its clinical programs. The company's Muzastotug Phase 2 dose expansion study showed a 33% overall response rate in MSS CRC patients using a 20 mg/kg loading dose regimen.

Key financial metrics include a cash balance of $85.2 million providing runway into late 2026, net revenue of $0.1 million (down from $18.1 million in 2023), and reduced R&D expenses of $28.8 million (21% decrease from 2023). The company reported a net loss of $33.4 million for 2024.

Pipeline highlights include promising results for ADG126 in combination with pembrolizumab, showing good tolerability with only a 6% discontinuation rate. The company is advancing its SAFEbody technology platform, with two T cell engager programs: ADG138 (HER2-targeted) and ADG152 (CD20-targeted) in development.

Ongoing collaborations with Exelixis, Sanofi, and Roche continue to progress, with milestone payments received and potential future payments totaling up to $2.5 billion plus tiered royalties.

Adagene (Nasdaq: ADAG), a pioneer in antibody-based therapies, has announced its upcoming presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The presentation, titled 'ADG126 SAFEbody®: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance', is scheduled for 11:30 AM - 11:50 AM Eastern Time at the Sheraton Boston Hotel.

The summit brings together pharmaceutical companies, biotech firms, academia, and investors focused on advancing cancer immunotherapy treatments. The presentation will be held in Track 2, Back Bay Ballroom AB, with slides becoming available on the company's website afterward.

Adagene (Nasdaq: ADAG), a pioneer in antibody-based therapy development, has announced its participation in Leerink's Global Healthcare Conference 2025. The event will take place from March 10-12 in Miami, Florida.

Dr. Peter Luo, who serves as the company's Chairman, CEO, and President of R&D, will engage in one-on-one investor meetings and deliver a corporate presentation. The presentation is scheduled for Wednesday, March 12, from 10:40-11:20 AM Eastern Time at W South Beach.

Investors and interested parties can access the presentation webcast through the Investors section of Adagene's website (www.adagene.com), where it will remain available for a minimum of 30 days.

Adagene (NASDAQ: ADAG) has announced an investigator initiated Phase 2 neoadjuvant trial of ADG126 for stage II or III colorectal cancer patients. The trial, identified as NCT06846268, will begin enrollment in April 2025 with expected primary completion in mid-2027.

The study will evaluate ADG126 in combination with KEYTRUDA® before surgery, with a primary endpoint measuring Major Pathologic Response (MPR) in up to 20 patients. MPR is defined as ≤10% residual viable tumor in surgical specimens. Secondary endpoints include complete pathological response, disease-free survival, and safety/tolerability.

Led by Dr. Yong Wei Peng from the National University Cancer Institute, Singapore, the trial will also explore pharmacodynamic effects on the tumor microenvironment's immune profile and ADG126's pharmacokinetic profile in tumor tissues.

Adagene (NASDAQ: ADAG) announced updated clinical data for their Phase 1b/2 study of Muzastotug (ADG126) in combination with KEYTRUDA® for colorectal cancer treatment. The study showed promising results with a 33% overall response rate in microsatellite stable colorectal cancer patients, achieving four confirmed partial responses out of twelve patients using a 20 mg/kg loading dose followed by 10 mg/kg Q3W + pembrolizumab.

The treatment demonstrated a favorable safety profile with no Grade 4/5 treatment-related adverse events and no discontinuations to date. Pruritus was the most common side effect, occurring in 25% of patients. The company plans to expand the study to include patients with liver metastases. All responding patients remain on treatment at maintenance doses of either 10 mg/kg Q3W or Q6W in combination with pembrolizumab.